A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07123103. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Study identification
- NCT ID
- NCT07123103
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 18, 2025 (Actual)
- Primary completion
- Nov 30, 2027 (Estimated)
- Completion
- Feb 29, 2028 (Estimated)
- Last update posted
- Nov 16, 2026
2025 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #5 | Rogers | Arkansas | 72758 | Recruiting |
| Exelixis Clinical Site #9 | Los Angeles | California | 90033 | Recruiting |
| Exelixis Clinical Site #6 | Washington D.C. | District of Columbia | 20057 | Recruiting |
| Exelixis Clinical Site #4 | Orlando | Florida | 32827 | Recruiting |
| Exelixis Clinical Site #3 | Grand Rapids | Michigan | 49546 | Recruiting |
| Exelixis Clinical Site #10 | East Brunswick | New Jersey | 08816 | Recruiting |
| Exelixis Clinical Site #7 | New Brunswick | New Jersey | 08901 | Recruiting |
| Exelixis Clinical Site #2 | Huntersville | North Carolina | 28078 | Recruiting |
| Exelixis Clinical Site #8 | Houston | Texas | 77030 | Recruiting |
| Exelixis Clinical Site #1 | San Antonio | Texas | 78229 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07123103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2026 · Synced Nov 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.